CR rates with respect to clinical and biologic characteristics of 286 enrolled and evaluable ALL patients treated according to the ALL0496 protocol
| . | Number . | CR rate, % . | χ2 analysis, P . |
|---|---|---|---|
| Age (y) | |||
| ≤ 30 | 111/135 | 82.2 | |
| 31-50 | 76/109 | 69.7 | .031 |
| 51-60 | 28/42 | 66.7 | |
| WBC | |||
| ≤ 10 | 94/123 | 76.4 | |
| 11-30 | 39/56 | 69.6 | |
| 31-50 | 17/25 | 68.0 | .332 |
| 51-100 | 29/33 | 87.9 | |
| > 100 | 36/48 | 75.0 | |
| Phenotype | |||
| B | 177/233 | 75.5 | .767 |
| T | 39/53 | 73.6 | |
| MDR1 expression (P-gp) | |||
| Negative | 125/157 | 79.6 | .001 |
| Positive | 23/43 | 53.5 | |
| MDR1 function (Rhd-123) | |||
| Negative | 103/133 | 77.4 | .090 |
| Positive | 14/23 | 60.9 | |
| CD34− | 66/76 | 86.8 | .004 |
| CD34+ | 140/200 | 70.0 | |
| BCR/ABL− | 159/204 | 77.9 | .088 |
| BCR/ABL+ | 51/75 | 68.0 | |
| t(4;11)− | 149/201 | 74.1 | .279 |
| t(4;11)+ | 13/15 | 86.7 |
| . | Number . | CR rate, % . | χ2 analysis, P . |
|---|---|---|---|
| Age (y) | |||
| ≤ 30 | 111/135 | 82.2 | |
| 31-50 | 76/109 | 69.7 | .031 |
| 51-60 | 28/42 | 66.7 | |
| WBC | |||
| ≤ 10 | 94/123 | 76.4 | |
| 11-30 | 39/56 | 69.6 | |
| 31-50 | 17/25 | 68.0 | .332 |
| 51-100 | 29/33 | 87.9 | |
| > 100 | 36/48 | 75.0 | |
| Phenotype | |||
| B | 177/233 | 75.5 | .767 |
| T | 39/53 | 73.6 | |
| MDR1 expression (P-gp) | |||
| Negative | 125/157 | 79.6 | .001 |
| Positive | 23/43 | 53.5 | |
| MDR1 function (Rhd-123) | |||
| Negative | 103/133 | 77.4 | .090 |
| Positive | 14/23 | 60.9 | |
| CD34− | 66/76 | 86.8 | .004 |
| CD34+ | 140/200 | 70.0 | |
| BCR/ABL− | 159/204 | 77.9 | .088 |
| BCR/ABL+ | 51/75 | 68.0 | |
| t(4;11)− | 149/201 | 74.1 | .279 |
| t(4;11)+ | 13/15 | 86.7 |